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Introduction: Remodeling of cellular metabolism appears to be a consequence and possibly a cause of oncogenic
transformation in human cancers. Specific aspects of altered tumor metabolism may be amenable to therapeutic
intervention and could be coordinated with other targeted therapies. In breast cancer, the genetic landscape has
been defined most comprehensively in efforts such as The Cancer Genome Atlas (TCGA). However, little is known
about how alterations of tumor metabolism correlate with this landscape.
Methods: In total 25 cancers (23 fully analyzed by TCGA) and 5 normal breast specimens were analyzed by gas
chromatography/mass spectrometry and liquid chromatography/mass spectrometry, quantitating 399 identifiable
metabolites.
Results: We found strong differences correlated with hormone receptor status with 18% of the metabolites
elevated in estrogen receptor negative (ER-) cancers compared to estrogen receptor positive (ER+) including many
glycolytic and glycogenolytic intermediates consistent with increased Warburg effects. Glutathione (GSH) pathway
components were also elevated in ER- tumors consistent with an increased requirement for handling higher levels
of oxidative stress. Additionally, ER- tumors had high levels of the oncometabolite 2-hydroxyglutarate (2-HG) and
the immunomodulatory tryptophan metabolite kynurenine. Kynurenine levels were correlated with the expression
of tryptophan-degrading enzyme (IDO1). However, high levels of 2-HG were not associated with somatic mutations
or expression levels of IDH1 or IDH2. BRCA1 mRNA levels were positively associated with coenzyme A, acetyl coenzyme
A, and GSH and negatively associated with multiple lipid species, supporting the regulation of ACC1 and NRF2 by BRCA1.
Different driver mutations were associated with distinct patterns of specific metabolites, such as lower levels of several
lipid-glycerophosphocholines in tumors with mutated TP53. A strong metabolomic signature associated with proliferation
rate was also observed; the metabolites in this signature overlap broadly with metabolites that define ER status as receptor
status and proliferation rate were correlated.
Conclusions: The addition of metabolomic profiles to the public domain TCGA dataset provides an important new tool for
discovery and hypothesis testing of the genetic regulation of tumor metabolism. Particular sets of metabolites may reveal
insights into the metabolic dysregulation that underlie the heterogeneity of breast cancer.Introduction
It is now well established that significant heterogeneity
exists among human breast cancers. This heterogeneity
is observable at every level of examination from the macro-
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unless otherwise stated.include The Cancer Genome Atlas (TCGA) where a
number of high-throughput ‘omic’ technologies were
systemically applied to hundreds of primary cancer speci-
mens [1]. Mutation, germ line polymorphisms, DNA copy
number, RNA expression, DNA methylation, and protein
expression analyses were performed in parallel on a large
and carefully curated set of breast cancer specimens to
produce the most comprehensive molecular portrait of
the disease to date.
One significant metric that was not included in TGCA
was an unbiased analysis of tumor metabolism. While
metabolic flux cannot be measured in fixed or frozend. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Tang et al. Breast Cancer Research 2014, 16:415 Page 2 of 15
http://breast-cancer-research.com/content/16/4/415specimens, steady-state levels of numerous key metabo-
lites may provide insight into these fundamental pheno-
typic traits. A number of studies in cancer have uncovered
relationships between genetic abnormalities and various
metabolic reprogramming suggesting that key metabolic
process can be altered as a result of specific transform-
ation events [2-6]. Relatively nonspecific cancer-related
events such as increased proliferation may also underlie
some of the inferred/observed metabolic remodeling. Glu-
cose uptake, serine and glutamine auxotrophy, mitochon-
drial oxidative phosphorylation, and cancer-associated
fibroblasts all appear to have roles in defining breast can-
cer metabolism [7-11]. However, it is not clear whether
these regulatory relationships can be observed in all or
subsets of human tumors.
Breast cancers are broadly categorized as luminal ver-
sus basal types possibly derived from different precursor
cells or at least different committed lineages [12-14].
Within these broad categories, alterations in specific
driver genes are believed to produce the heterogeneity
observed amongst and within breast tumor subtypes.
While the identity and frequency of driver alterations
are generally different in basal and luminal cancers,
there is still considerable overlap. For example, TP53 mu-
tations are very common in basal tumors and PI3KCA
mutations are common in luminal cancer but neither is
subtype exclusive. In contrast, MYC (8q24) amplification
is common in both types [1]. Each of these genetic drivers
has been associated with specific changes in cellular me-
tabolism and therefore may have dominant effects that
can be observed across tumor types.
Metabolomic profiling via mass spectrometry or nu-
clear magnetic resonance (NMR) is now an established
approach that has been employed in several studies to
analyze primary human breast tissues (normal and can-
cer) [15,16]. Building upon transcriptional profiling of
breast cancer, there have also been several efforts to in-
tegrate steady-state metabolite levels with specific breast
cancer subtypes defined by mRNA expression. Expres-
sion subtypes are dominated by estrogen receptor and
ERBB2 status and thus, metabolic profiling was per-
formed to seek an additional level of information to refine
these existing classifications. These analyses identified a
subclassification of luminal A-type cancers based on me-
tabolite levels and found higher levels of Warburg-
associated metabolites in more aggressive cancer types
[9,17]. A separate study of breast cancer lipidomic identi-
fied the association between palmitate-containing phos-
phatidylcholines with estrogen receptor negative and
cancer progression and patient survival [18]. However,
none of these studies established associations of par-
ticular metabolites or metabolic pathways with specific
somatic mutations or expression levels that have been
extensively characterized in TCGA.In order to more fully explore the relationship between
genetics, tumor type, and metabolic state, we took ad-
vantage of our participation in the breast cancer TCGA
to perform joint analyses of metabolomics and genetics
in a series of primary cancers. From the current study,
we were able to identify several genetic determinants of
the metabolic heterogeneity of human breast tumors
that confirm and extend prior in vitro and in vivo
observations.
Methods
Specimen selection and handling
Breast tissues were collected, stored and used under Duke
University Medical Center Institutional Review Board (IRB)
approved protocols (Pro00012025 and Pro00021284). A
waiver of consent was obtained from the Duke IRB to con-
duct the study (Pro00021284) and subjects were not re-
consented for participation. Twenty-five breast cancers
(diagnosed and treated from 1989 to 1998) were se-
lected for the current study based on their inclusion in
The Cancer Genome Atlas (TCGA). Specifically, we se-
lected cases that were either estrogen receptor (ER)
positive or negative for both estrogen and progester-
one receptors (PR) based on the clinical assay per-
formed at the time of initial diagnosis (clinical and
demographic information is provided in Table S1 in
Additional file 1). Two of the ER + positive cancers
were classified as PR negative by the clinical assay. In
addition to the cancers, we selected five breast speci-
mens obtained from reduction mammoplasties containing
substantial amounts of normal epithelium. Each block of
tissue was cryostat sectioned to analyze tumor epithelial
content based on microscopic examination with a cut-
off of 70% tumor nuclei for inclusion. Additional sec-
tions were also taken and stored desiccated at −80°C
for future use. The remainder of the tissue block was
submitted frozen to Metabolon Inc. (Durham, NC,
USA) for extraction and metabolomic analysis. After
trimming away the cryogenic-embedding compound
(OCT), the weight of each sample (27 to 115 mg) was
determined and used to normalize the extraction re-
agent volume.
Proliferation analysis
Thin sections were fixed in acetone and then stained
with MIB-1 antibody (Dako, Glostrup, Denmark) that
recognizes the Ki-67 proliferation antigen. The mouse
monoclonal antibody was used at a final concentration
of 200 μg/ml and detected with a biotinylated goat anti-
mouse secondary antibody. Following chromogenic de-
tection, each section was scored for the percentage of
nuclear-stained epithelial cells. Two hundred epithelial
cells were counted in each section spanning at least two
high-powered (40X) fields. The proliferation rate was
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ing nuclear staining.
Metabolomic profiling
The sample preparation process at Metabolon was car-
ried out using an automated MicroLab STAR™ system
from the Hamilton Company (Reno, NV, USA). Recov-
ery standards were added prior to the first step in the
extraction process for quality control purposes. Sample
preparation was conducted using a proprietary (Metabo-
lon, Inc.) series of organic and aqueous extractions to re-
move the protein fraction while allowing maximum
recovery of small molecules. The resulting extract was
divided into two fractions; one for analysis by liquid
chromatography (LC) and one for analysis by gas chro-
matography (GC). Samples were placed briefly on a
Zymark TurboVap (Phoenix Equipment, Inc., Rochester,
NY, USA) to remove the organic solvent. Each sample
was then frozen and dried under vacuum. Samples were
then prepared for the appropriate instrument, either LC/
mass spectrometry (MS) or GC/MS.
The LC/MS portion of the platform is based on a Wa-
ters ACQUITY UPLC (Waters, Milford, MA, USA) and
a Thermo-Finnigan LTQ mass spectrometer (Thermo
Fisher Scientific, Waltham, MA, USA), which consists of
an electrospray ionization (ESI) source and linear ion
trap (LIT) mass analyzer. The sample extract was split
into two aliquots, dried, then reconstituted in acidic or
basic LC-compatible solvents, each of which contained
11 or more injection standards at fixed concentrations.
One aliquot was analyzed using acidic positive ion opti-
mized conditions and the other using basic negative ion
optimized conditions in two independent injections using
separate dedicated columns. Extracts reconstituted in
acidic conditions were gradient eluted using water and
methanol both containing 0.1% formic acid, while the
basic extracts, which also used water/methanol, con-
tained 6.5 mM ammonium bicarbonate. The MS ana-
lysis alternated between MS and data-dependent MS2
scans using dynamic exclusion.
The samples destined for GC/MS analysis were redried
under vacuum desiccation for a minimum of 24 hrs prior to
being derivatized under nitrogen using bis(trimethylsilyl) tri-
flouroacetamide (BSTFA). The GC column was 5% phenyl
and the temperature ramp was from 40° to 300°C in a
16 min period. Samples were analyzed on a Thermo-
Finnigan Trace DSQ fast-scanning single-quadrupole mass
spectrometer using electron impact ionization (Thermo
Fisher Scientific). The instrument was tuned and calibrated
for mass resolution and mass accuracy on a daily basis. The
information output from the raw data files was automatic-
ally extracted as discussed below.
For ions with counts greater than 2 million, an accur-
ate mass measurement could be performed. Accuratemass measurements could be made on the parent ion as
well as fragments. The typical mass error was less than
5 ppm. Fragmentation spectra (MS/MS) were typically
generated in a data-dependent manner, but if necessary,
targeted MS/MS was employed, such as in the case of
lower level signals.
Identification of known chemical entities was based on
comparison to metabolomic library entries of purified
standards. More than 1,000 commercially available puri-
fied standard compounds have been registered into a
database for distribution to both the LC and GC plat-
forms for determination of their analytical characteris-
tics. The combination of chromatographic properties
and mass spectra gave an indication of a match to the
specific compound or an isobaric entity.
Measurement of 2-hydroxyglutarate
Quantification of L/D-2-hydroxyglutarate (2-HG) in bio-
logical media/tissues was performed by LC-ESI-MS/MS
as described [19] with modifications to accommodate
different sample matrices involved in the study. The
method utilizes a chiral derivatization agent to produce
diastereoisomers with L- and D-isomers of 2-HG,
which can be separated by conventional reverse-phase
LC. D-2-HG, L-2-HG, and diacetyl-L-tartaric anhyd-
ride (DATAN) were from Sigma-Aldrich (St Louis,
MO, USA). Racemic mixtures of L- and D-2-HG-d4
were prepared by mixing 1 mg of α-ketoglutarate-d6
(Sigma-Aldrich/Isotec) with 1 mg of NaBH4 (Sigma-
Aldrich) in 0.2 mL anhydrous MeOH (Sigma-Aldrich)
followed by 30 min incubation at 60°C. Tissue or cell
line homogenates, 200 μL of deionized water, 1 mL of
chloroform, and 4 mm ceramic beads were vigorously
mixed for 45 sec at speed 4 in FastPrep 120 ‘bead-
beater’ instrument (Thermo Savant, Holbrook, NY,
USA). After centrifugation (5 min at 16,100 × g),
200 μL of the aqueous (upper) layer was transferred
into 1.5-mL glass vial and dried (50°C, 60 min). The
dry residue was treated with 50 mg/mL of freshly pre-
pared DATAN in dichloromethane/glacial acetic acid
(4/1 by volume) and heated at 75°C for 30 min. After
drying (50°C, 15 min) the residue was dissolved in
100 μL LC mobile phase A (see below) for analysis by
LC/MS/MS with an Agilent 1200 series HPLC (Agi-
lent Technologies, St Clara, CA, USA) and Sciex/Applied
Biosystems API 3200 QTrap (Applied Biosystems, Foster
City, CA, USA). Mobile phase A: water, 3% acetonitrile,
280 μL ammonium hydroxide (approximately 25%), pH
adjusted to 3.6 by formic acid (approximately 98%). Mo-
bile phase B: methanol. Analytical column: Kinetex C18,
150 × 4.6 mm, 2.6 μm, and SafeGuard C18 4 × 3 mm
guard-column from Phenomenex (Torrance, CA, USA).
Column temperature: 45°C. Elution gradient at 1 mL/min
flow rate: 0 to 1 min 0% B, 1 to 2 min 0 to 100% B, 2 to
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B. Injection volume: 10 μL. The Q1/Q3 (m/z) transitions
monitored: 363/147 (2-HG) and 367/151 (2-HG-d4). A
set of calibrator samples in corresponding matrix were
prepared for calibration by adding appropriate amounts of
pure D-2-HG at the following concentration levels: 0,
0.16, 0.54, 1.8, 6, and 20 ug/mL. These samples were ana-
lyzed alongside the experimental samples.
Data analysis
For pairwise comparison of metabolites from different
sample categories (normal, ER+, ER-), we used Welch’s t
test. The false discovery rate was estimated using the q
value [20].
The data were subjected to hierarchical clustering
using Cluster 3.0 and displayed using TreeView [21].
The significance analysis of microarray (SAM) analyses
were performed as described using indicated selection
criteria [22]. For specific metabolite associations with
genetic events, data were analyzed in GraphPad Prism
(GraphPad Software, San Diego, CA, USA) for correl-
ation and significance.
Genetic mutation and copy number, RNA expression
data, and designation of tumor intrinsic subtype were all
derived from the publically available TCGA data sets.
Primary data were downloaded from the TCGA data
portal [23] or analyzed using the online cBioPortal suite
of tools [24]. For the cBioPortal, some analyses were per-
formed on the ‘TCGA Nature 2012’ data set and others
on the ‘TCGA Provisional’ data set.
For analysis of the correlation between each pair of
metabolites, Pearson correlations of the level of each
pair of metabolites (log2 normalized value) among 399
metabolites from 25 tumors and 5 normal breast tissues
were generated. The correlation coefficients were hier-
archically clustered by Cluster 3.0 to produce the heat-
map plot. For analysis of correlation between individual
metabolite and proliferation rate, Pearson correlations
between the level of individual metabolite (log2 normal-
ized value) and Ki-67% (log2 value) were calculated. The
supervised cluster plot was generated based on the correl-
ation between individual metabolite levels and prolifera-
tion rate (Ki-67%) and displayed by TreeView.
For combined analysis of receptor status and prolifera-
tion, normalized metabolic data were natural log trans-
formed yielding a symmetric distribution of the data
about the mean. We used normal theory linear regres-
sion to assess the extent to which the metabolic assay
data could be predicted by one, the other or both of the
tumor’s receptor status and proliferation rate (Ki-67%).
We analyzed each metabolite separately and fit four
models for each: (1) the model with intercept only; (2)
the model with intercept and receptor status; (3) the
model with intercept and log2 proliferation rate; and (4)the model with intercept, receptor status and log2 prolif-
eration rate. We calculated analysis of variance tables for
the two nested progressions of models: (1, 2, 4) and (1,
3, 4). We report the P values based on the associated F
tests for (a) models 2 over 1, (b) 4 over 2, (c) 3 over 1
and (d) 4 over 3. The P values in (a) and (c) are for the
regression of abundance of the metabolite on receptor
status and for the regression of abundance of the metab-
olite on proliferation rate, respectively. The P values in
(b) and (d) are for the regression of abundance of the
metabolite on receptor status while adjusting for prolif-
eration rate and for the regression of abundance of the
metabolite on the proliferation rate while adjusting for
receptor status, respectively.
Results
To date, over 900 primary breast cancers have been pro-
filed by the TCGA initiative over a four-year period
using an evolving set of molecular analyses. For this rea-
son, not all cancers were analyzed by all techniques. For
the current metabolomic study, we chose 25 cancers that
had passed quality control and were accepted for ana-
lysis by TCGA: 16 ER positive (all but two were also PR
positive) and 9 cancers that were both ER and PR nega-
tive, determined by standard immunopathologic analysis
after cytoreductive surgery. Of these, 23 cancers (15 ER +
and 8 ER-) were eventually subjected to comprehensive
genetic analysis by TCGA. In addition to the cancers, we
selected 5 samples of normal breast tissue (from reduction
mammoplasties not associated with cancer) that contained
a substantial amount of epithelium based on histologic
staining. We cut 20 sections from each block for in situ
analyses before extraction for the quantitative profiling of
small molecules (<1,000 Da) that was performed in a sin-
gle batch on the Metabolon platform generating data on
399 identifiable metabolites (Table S2 in Additional file 2
contains the primary data on metabolites).
Primary tissues in this study were distributed into
three main categories: (1) normal breast from reduc-
tion mammoplasties, (2) ER positive primary breast
cancers, and (3) estrogen and PR negative primary can-
cers. Of the 25 cancers, all were accepted for TCGA
study but only 23 were actually subjected to genetic
analysis. The cancers are representative of the major
subtypes of the disease based on the PAM50 classifica-
tion [25] including basal, HER2, luminal A and luminal
B. One sample was designated as ‘not-classified’ (NC).
None of the tumors were classified as the relatively un-
common ‘claudin low’ subtype.
Hierarchical clustering of the samples based on these
metabolites demonstrated that the 5 normal breast sam-
ples were tightly clustered together while the ER + tumors
exhibited significant heterogeneity: 6 of the ER + tumors
grouped with the 5 normal breast samples while the
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(Figure 1). This relative heterogeneity of ER + tumors is
consistent with previous classification based on gene ex-
pression [12,26]. Pictured below the hierarchical clustering
dendrogram for 23 of the cancers is TCGA data for the
most common gene-based abnormalities (mutation, ampli-
fication, homozygous deletion) found in breast cancer,
most of which are considered to be driver alterations. Also
shown is the PAM50 intrinsic subtype classifier (based on
gene expression) of the TCGA analyzed cancers (23 tu-
mors) as well as the not-classified (NC) tumor. From this
analysis, it is apparent that intrinsic expression tumor sub-
types do not define the classification of the tumors by me-
tabolite levels.Figure 1 Breast cancers (n = 25) and normal breast tissues (n = 5) wer
levels and overlaid with intrinsic subtype and status of the somatic m
mean-centered, selected based on at least two-fold changes in two sample
status, intrinsic subtypes, and identified somatic mutations in the indicated
Cancer Genome Atlas (TCGA).This composite diagram (Figure 1) demonstrates sev-
eral aspects of breast cancer observed across many stud-
ies: (1) hormone receptor expression tracks closely with
intrinsic subtype; (2) TP53 mutations are very frequent
in basal-type cancers; and (3) PIK3CA mutations are
common in luminal types. The metabolite-based cluster-
ing of these specimens places a group of luminal A can-
cers with the normal breast specimens and most of the
basal cancers together in a single branch. A middle
branch contains a combination of mostly luminal A and
B cancers. HER2 cancers, as assigned by expression sub-
type (n = 2) or genomic copy number (n = 4) also tend to
cluster in this middle branch. Overall, the cancers in the
study appear to have a distribution of receptor status,e grouped by unsupervised hierarchical clustering of metabolite
utations of genetic drivers. Normalized metabolite levels were
s and arranged by hierarchical clustering. The estrogen receptor (ER)
genes are shown for 23 tumors which were characterized by The
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unselected case series.
Estrogen receptor status reflects a broad metabolic
division in breast cancer
Our next step in the analysis was to compare metabolite
levels in the cancers based on ER status (ER + versus ER-),
the most consistent division in breast cancer from both
a biologic and therapeutic perspective (Figure 2A).
Overall, ER status was a very strong divisor in metabolic
space. The identity of the metabolites that vary by ER
status supports a series of systematic differences in bio-
energetics and biosynthetic pathways. Of the 399 named
metabolites quantified in this study, 75 exhibited a sta-
tistically significant difference between ER + and ER- tu-
mors (Table S3 in Additional file 3, unadjusted t tests
comparing levels between the three groups of samples,
ER+, ER-, and normal breast). Of these, only 8 metabolitesFigure 2 Supervised analysis of metabolites by estrogen receptor (ER
the mean of the five normal breast tumors, filtered and arranged by hierar
higher levels of metabolites in the glycogenolysis (B) and glycolysis (D) path
The names of elevated (labeled in red) and reduced (labeled in green) metab
the metabolism diagram (C). Increased levels of gamma-glutamyl-isoleucine (
found. Primary data and P values for these comparisons can be found in Tablwere increased in ER + tumors including 3 carnitine deriv-
atives, suggesting an increase in fatty acid transportation
in hormone receptor positive cancers. Short- and
medium-chain fatty acids were also elevated in ER +
tumors whereas long-chain fatty acids and monoacylgly-
cerols tended to be higher in ER- tumors indicating that
systematic differences in lipolysis and fatty acid oxidation
correlate with hormone receptor status.
ER- tumors had higher levels of glycogenolytic (malto-
pentose, maltotetraose, maltotriose and maltose, Figure 2B
and pathways in Figure 2C) and glycolytic metabolites
(glucose-6-phosphate, fructose-6-phosphate, fructose-1,6-
bisphosphate, and lactate) (Figure 2D). In contrast, there
was a lower level of glucose in the tumors, especially ER-
tumors (Figure 2D). Warburg metabolism is a means for
rapidly dividing cells, such as cancer cells, to accelerate
energy production through increased glycolysis and lactate
production, bypassing the normal oxidation of pyruvate in) status. (A) Tumor-specific metabolites were zero-transformed against
chical clustering based on 16 ER + and 9 ER- tumors. (B-D) Significantly
ways, as shown in (C), were found in the ER- compared to ER + tumors.
olites in the glycolysis (B) and glycogenolysis (D) pathways are shown in
E) and reduced (GSH) and oxidized (GSSG) glutathione (F) were also
e S2 in Additional file 2 and Table S3 in Additional file 3.
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mors is consistent with an elevated Warburg effect.
To validate our results, we compared our data to re-
cently published data on breast cancers collected using
the same metabolomic platform [27]. Among the signifi-
cant metabolites that tracked with hormone receptor
status in our data, 57 of these were found in the Teru-
numa dataset and exhibited broadly similar differences
between ER + and ER- cancers (27 reaching significance
in both data sets, Figure S1 in Additional file 4 and
Table S4 in Additional file 5). Therefore, these identified
subtype-specific metabolites can be validated using an
independent dataset.
Reduced glutathione (GSH) and gamma-glutamyl amino
acids in ER- tumors
ER- cancers also had higher levels of gamma-glutamyl
amino acids coupled with increased glutathione synthesis
(Figure 2E, Figure S2 in Additional file 4). Gamma-glutamyl
amino acids result from the transpeptidase-mediated cata-
lytic reaction of amino acids with glutathione (Figure S2 in
Additional file 4). These amino acid-glutathione conjugates
traverse the cell membrane and release the amino acid intra-
cellularly to regenerate glutathione [28]. Elevated levels of
these gamma-glutamyl conjugates indicate an increased up-
take of amino acids in ER- tumors. This may point to a po-
tential shift in fuel substrates for energy production that
favors amino acid catabolism. It is interesting to note that
the most elevated gamma-glutamyl amino acids were the
branched-chain amino acid (BCAA) conjugates of valine,
leucine and isoleucine. Additionally, ER- tumors had in-
creased glutathione (reduced, GSH) and oxidized glutathi-
one (GSSG) (Figure 2F) indicating a trend toward increased
glutathione synthesis, presumably to cope with the higher
levels of oxidative stress.
Metabolite correlations in breast cancers
We postulated that the level of multiple metabolites de-
rived from the same and different metabolic pathway
might be coordinated and serve as a better indicator of
metabolic activity than any single compound alone.
Pearson correlations were calculated for all pairwise com-
parisons between each of the 399 metabolites for all samples
(Table S5 in Additional file 6). The resulting correlation
coefficients were then used to group the 399 metabolites
into distinct groups by hierarchical clustering (cluster 3.0)
and then displayed with TreeView (Figure 3). We found
that multiple groups of metabolites were highly clustered
and correlated. These groups include many metabolites
that are known to be in the same metabolic pathways as
well as unexpected correlation between metabolites in dif-
ferent metabolic pathways. Metabolites from different
pathways clustered in the same groups might indicate two
different metabolic pathways are coordinated by the samegenetic alteration or affected similarly by the metabolic
reprogramming. For example, we found a cluster of metab-
olites comprising many intermediates of various lipids as-
sociated with glycerophosphocholines (Figure 3, cluster 3).
We also noted two separate clusters of amino acids
and di-amino acids (glycine-proline, glutamate-leucine,
alanine-tyrosine) (Figure 3, cluster 4) and N-acetyl-amino
acids (N-acetyl-aspartate, N-acetyl-ornithine, N-acetyl-
aspartyl-glutamate) (Figure 3, cluster 5). Both clusters may
indicate products of protein degradation and catabolism
and can be used to identify tumors with higher protein
catabolism.
Another prominent cluster is composed of acetyl-CoA,
CoA, FAD, AMP as well as GSH and GSSH (Figure 3,
cluster 6). The co-cluster of these metabolites suggests a
high degree of correlation between these energy metabo-
lites and anti-oxidative capacity among the tumor tissues.
We also noted connected clusters of metabolites related
to glycolysis (fructose, glucose-6-phosphate, fructose-
6-phosphate) and glycogenolysis (malto-triose, malto-
tetraose, malto-pentose) (Figure 3, cluster 8), both were
elevated in ER- cancers (Figure 2).
Metabolites associated with specific genetic events
A novel and unexpected finding was the level of the
oncometabolite 2-HG, elevated over 20-fold in ER + tu-
mors compared with normal tissue and over 200-fold in
ER- tumors (Figure 4A). A single ER- tumor exhibited
10-fold higher levels of 2-HG compared to any other
sample (unscaled data). We further confirmed the levels
of 2-HG in a subset of the breast cancer extracts using
an independent assay based on MS performed at Duke
and found a very high correlation between the results
from these two independent platforms (Figure S3A in
Additional file 4). Using this targeted assay, we also mea-
sured 2-HG in a series of breast cancer cell lines and
found that two basal lines (Hs578T and BT20) had the
highest levels, consistent with data from the primary
cancers (Figure 4B). A high level of 2-HG has been asso-
ciated with missense mutations in IDH1 or IDH2 in gli-
oma and several other tumor types [29] and may be an
effector of tumor cell dedifferentiation [30]. Within the
TCGA breast data set, two cancers (<0.5%) were found
to harbor missense mutations in IDH1 that have a high
probability of affecting the function of the enzyme
(R132C, Y235C). Since these data were based on whole
genome sequencing that could overlook specific muta-
tions, we performed targeted sequencing in the tumor
(TCGA-B6-A1KF) with very high levels of 2-HG to look
for the recurrent mutations found in other tumors in
IDH1 and IDH2. This tumor was wild type for both
genes in these regions (Figure S3B in Additional file 4)
suggesting an alternative mechanism leading to 2-HG































































Figure 3 Hierarchical clustering of metabolites based on correlation coefficients. The correlation coefficients were calculated using Pearson
product-moment of each pair of metabolites (log base 2 normalized) among 399 metabolites from 25 breast cancers and 5 normal breast tissues.
Eight clusters of highly correlated metabolites are highlighted on the right panel.
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in these specimens also did not show a significant cor-
relation with 2-HG levels.
A number of reports indicate that alterations in spe-
cific genes or genetic pathways can result in detectable
metabolic changes in cancer. Our study with both de-
tailed gene expression and metabolomic data provided a
powerful means to test these associations and discover
new ones. One of the least complex of such relationships
is the link between the level of the tryptophan-degrading
enzyme indoleamine 2,3-dioxygenase (IDO1) and levels of
the immunomodulatory metabolite, kynurenine (Figure 4C).
Whereas the precursor molecule tryptophan did not vary
between ER + and ER- cancers, median levels of kynurenine
were significantly elevated in ER- tumors (Figure 4D). From
RNAseq data of the 23 cancers in our study, we found a
significant correlation between IDO1 expression and
kynurenine levels (Figure 3E, r = 0.55, P = 0.01). Comparinglevels of IDO1 mRNA within the TCGA data set (n = 748)
revealed a significant positive correlation of IDO1 mRNA
levels with vimentin expression (a hallmark of basal can-
cers). This finding suggests that kynurenine accumulation
commonly occurs in basal cancers and could lead to re-
duced immunosurveillance in this tumor type.
BRCA1 has been implicated in a number of metabolic
processes including fatty acid synthesis and response to
oxidative stress. Using the available RNAseq data, we
correlated expression of BRCA1 with metabolite levels
in the 23 TCGA cancers (Table S6 in Additional file 7).
There was evidence of strong association between high
levels of BRCA1 mRNA and elevated acetyl CoA, CoA,
3′ dephospho-CoA, and several acylcarnitines all indica-
tive of higher levels of fatty acid β-oxidation (Figure 5).
This is consistent with the reported ability of BRCA1
to inhibit acetyl-coenzyme A carboxylase 1 (ACC1/
ACACA) leading to reduced fatty acid synthesis and
Figure 4 Specific metabolic/genetic associations. (A) The mean level of 2-hydroxyglutarate (2-HG) in 5 normal tissues, 16 estrogen receptor
(ER) + and 9 ER- tumors. (B) The level of 2-HG in breast cancer cell lines (4 luminal type and 5 basal type cells). (C) Kynurenine is derived from
tryptophan by indoleamine 2,3-dioxygenase (IDO) or tryptophan 2,3-dioxygenase (TDO) enzymatic activity. (D) The level of tryptophan and kynurenine
in 5 normal tissues, 16 ER + and 9 ER- tumors. (E) The correlation between the level of kynurenine and IDO1 gene expression measured by RNAseq
in 23 tumors analyzed by The Cancer Genome Atlas (TCGA). (F) The correlation between RNA expression of the mesenchymal/basal marker
vimentin and IDO1 in TCGA breast cancers.
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http://breast-cancer-research.com/content/16/4/415increased fatty acid β-oxidation resulting in the accu-
mulation of acetyl-CoA and CoA [31]. In contrast,
there were strong inverse correlations between BRCA1
levels and membrane components, long-chain fatty
acids, and amino acids further supporting the role of
BRCA1 in regulating the balance between fatty acid
synthesis and oxidation (Figure 5) [32]. In addition,
GSH and another antioxidant, 3-(4-hydroxyphenyl)lac-
tate were also positively correlated with BRCA1 mRNA
levels, supporting its role in activating NRF2, the mas-
ter regulator of the oxidative stress response and GSH
synthesis [33-35]. BRCA1 mRNA levels did not correl-
ate with proliferation or ER status indicating that this
is an independent set of variables. Furthermore, theBRCA1 mRNA did not correlate with the mRNA levels
of genes in the fatty acid biosynthesis pathways; con-
sistent with posttranscriptional regulation (Figure S4
in Additional file 4).
To further explore associations with the most com-
mon genetic events in breast cancer, we performed SAM
analyses (Table S7 in Additional file 8) to identify metabo-
lites associated with the somatic driver alterations (shown
in Figure 1, used as categorical variables that is, mutant
versus wild type, amplified/deleted versus diploid). Many
of the genetic events are loosely associated with specific
tumor subtypes (for example, PIK3CA mutations were
not found in basal cancers) such that metabolite correla-
tions with specific genetic features may be confounded by
P=0.001 P=0.007 P=0.03
P=0.004 P=0.02 P=0.03
Figure 5 Correlation between selected metabolite levels and BRCA1 mRNA expression. Three representative metabolites (coenzyme A
(CoA), reduced glutathione (GSH) and oleoyl-carnitine) that are positively and three (N-acetylneuraminate, arachidonate and palmitate) that are
inversely correlated with BRCA1 mRNA levels from The Cancer Genome Atlas (TCGA) RNAseq data on 23 cancers are shown. The full list of
metabolites correlated with BRCA1 is provided in Table S6 in Additional file 7 showing listing both normalized metabolite levels and metabolite
levels with an additional log2 transformation to reduce the impact of outliers.
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support several relationships between metabolite profiles
and tumor genetics. Most notably, compared to tumors
with wild-type p53, cancers with TP53 alterations show a
very specific pattern of decreased lipid glycerophosphocho-
lines that is not apparent when classifying the cancers by
ER status, (Figure S5 in Additional file 4). Other significant
associations were observed between PIK3CA mutation and
malonylcarnitine and ERBB2 amplification with docosapen-
taenoate, fucose, and 1-oleoylglycerophosphoethanolamine
(Figure S6 in Additional file 4).
Metabolites associated with proliferation in tumors
Proliferation rate could impact the level of many metab-
olites. We measured proliferation by in situ detection of
Ki-67 followed by quantitative evaluation of the percent-
age of epithelial cells positive for this antigen. As previ-
ously demonstrated in many studies, proliferation tends
to be significantly higher in ER- compared to ER + tu-
mors (mean of 32% versus 14%, P = 0.009 in our cohort)
and epithelial cells in normal breast tissue have a very
low rate of proliferation (Figure 6C). Supervised cluster-
ing and correlation analysis of the metabolites with pro-
liferation rate demonstrated sets of metabolites that
were positively and inversely correlated with prolifera-
tion (Figure 6A and B, and Table S8 in Additional file 9).
Predictably, the level of glucose was lower in rapidly pro-
liferating cancers whereas lactate was positively correlatedwith proliferation (Figure 6D). N-acetyl amino acids and
2′-deoxyinosine were highly enriched in rapidly proliferat-
ing tumors. The biological roles of N-acetyl amino acids
are largely unknown. However, aminoacylase-1 (encoded
by ACY1), which is responsible for the degradation of
these N-acetyl amino acids, has been found to be inac-
tivated in several tumor types [36,37]. High levels of
2′-deoxyinosine (dI) may be an indication of misincor-
poration of dI into the DNA of ER- tumor cells, a lesion
capable of generating A– > G transitions in DNA [38].
ER status was highly correlated with proliferation and
therefore many of the same metabolites were associated
with both of these parameters. We further analyzed the
data to determine whether these two parameters had
any degree of independence, and if so, for which sets of
metabolites. Linear regression analyses show that, while
correlated with one another, ER and proliferation status
act as complementary explanatory factors for many of
the metabolites (Figure S7 in Additional file 4). A rela-
tively small number of metabolites were highly corre-
lated with one parameter but not the other, most
notably 2-HG with ER status but not proliferation (Table
S9 in Additional file 10).
Discussion
Links between cancer genetics and altered metabolism
have been established primarily in model and experi-









Figure 6 Proliferation rate is correlated with the level of many metabolites. (A) Supervised clustering of normalized metabolite levels as
ordered by the proliferation rate (Ki-67%) (from low (left) to high (right)). (B) Zoomed views of the metabolites that are most positively (orange
bar) or negatively (blue bar) correlated with proliferation. (C) Proliferation associated with receptor status and cancer status from the 30 samples
in this study. (D) The correlation of representative metabolites positively or negatively associated with proliferation rate.
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http://breast-cancer-research.com/content/16/4/415human cancers. The current study makes use of the
comprehensive genetic data from TCGA on breast can-
cer [1] to test reported relationships and discover new
and unexpected associations between genetics and me-
tabolism. TCGA data provides an excellent platform in
this regard for three reasons: (1) the tissues were sub-
jected to stringent quality control criteria including
tumor nuclei exceeding 70% and the absence of signifi-
cant necrosis, (2) multiple analytes were measured in
parallel on the same cancers including DNA sequence
for mutations, DNA copy number assessment, RNA ex-
pression including RNAseq and microarray analysis, methy-
lation, and protein and phosphoprotein levels, and (3) the
data are in the public domain in easily accessible formats
with standardized specimen identifiers that can be directly
linked and co-analyzed with other types of newly generated
data such as the metabolite levels that we measured in the
current study. We include the primary data on these sam-
ples so that anyone can perform their own joint analysis on
metabolites and genes of interest.The frozen tissues were analyzed on a metabolomics
platform that has been used in other cancer-related
studies [39-41] and at the time of the analysis, included
identification and quantitation of 399 named biochemi-
cals (Mr <1,000 Da). Unsupervised clustering by metabol-
ite levels revealed two major categories, one containing
the normal breast tissues and a subset of the ER + cancers,
and the other containing all of the ER- cancers and the
remaining ER + ones. Overlaying the TCGA data on these
clusters revealed that all of the cancers clustering with
normal breast were of the luminal A intrinsic subtype.
The remaining luminal A and all of the luminal B cancers
fell in the other major cluster along with all of the basal
cancers and the two cancers designated as HER2 by
PAM50. That the luminal A cancers do not all cluster to-
gether is consistent with a metabolomic study employing
high resolution magic angle spinning magnetic resonance
spectroscopy of predominantly luminal cancers [17]. In
this study, three distinct categories of luminal A cancers
were described by hierarchical clustering driven primarily
Tang et al. Breast Cancer Research 2014, 16:415 Page 12 of 15
http://breast-cancer-research.com/content/16/4/415by varying levels of glycolytic activity. Widely different
proliferation rates in the ER + cancers may at least par-
tially underlie these luminal sub-clusters.
The basal subtype, a subset of the ER- cancers, demon-
strated significant homogeneity with 4 of the 5 PAM50
basal cancers clustering on one sub-branch of the metabo-
lomic hierarchical tree. A HER2 cancer was the only other
member of this sub-branch but this cancer does share the
common basal trait of having a TP53 mutation. Overlay-
ing the most common genetic driver alterations in breast
cancer on this cluster diagram allowed a visual assessment
of whether branches may also be driven by specific onco-
genic events. TP53 mutations and basal cancer status are
nearly coincident and as described, the basal cancers are
tightly clustered. Therefore, it is difficult to disentangle
genetics from intrinsic subtype in this instance. Other not-
able groupings that may be associated with a specific
genetic driver include MYC amplification and PIK3CA
mutation. PIK3CA mutations are tightly linked to the
luminal subtypes whereas MYC amplification is com-
mon in both basal and luminal cancers. It may be
noteworthy that none of the MYC amplified tumors
clustered with the normal breast tissue.
Supervised classification and t tests based on the three
categories of specimens (ER+, ER/PR-, normal) exhibited
significant signals for many metabolites. Over half of the
399 identified metabolites were different between normal
and cancer. Moreover, >18% of the metabolites varied
significantly between ER + and ER- cancers. These dra-
matic differences are consistent with previous reports
showing strong remodeling of central metabolism be-
tween normal breast tissue and breast cancer [16] and
between tumor subtypes [9]. Notably, glycolytic- and
glycogenolytic-associated metabolites including lactate
were higher in ER- cancers with the prominent excep-
tion of low tumor glucose. The increased lactate produc-
tion from ER- cancer may be caused by increased
glycolysis and confirm our previous finding of a strong
hypoxia program and the high ‘Warburg’ phenotype previ-
ously described in other studies of ER- cancer [7,9,16,27].
From TCGA data (for 23 of 25 of the cancers), we
were able to confirm or identify known and unexpected
associations between metabolite levels and various gen-
etic events. Proof of principle for this approach was
demonstrated by the correlation between kynurenine
and the mRNA of its synthetic enzyme, IDO1. IDO1 ex-
pression was also found to correlate with the basal
phenotype common to ER- cancers and the high levels
of kynurenine produced could result in reduced immu-
nosurveillance of these cancers [42]. Increased serum
kynurenine/tryptophan ratio has been noted during the
progression of several tumor types [43,44]. Our findings
support a connection between high IDO levels and
kynurenine in ER- tumors. Other a priori associationsthat were tested included PKM2 exon 9 versus 10
splice variant levels with proliferation and metabolite
levels [45], IDH1 and 2 mRNA and mutations with 2-
hydroxyglutarate levels [29], and levels of GGT1 mRNA
and the gamma-glutamyl amino acids [46]. Of these, the
strongest association was between GGT1 and a subset of
the conjugated amino acids including leucine and isoleu-
cine (Figure S8 in Additional file 10). GGT1 expression
has been associated with a subset of basal cancers and our
data indicating elevated levels of gamma-glutamyl amino
acids in ER- cancers provides functional support for this
genetic link.
A number of driver mutational events have been im-
plicated in breast cancer development including amplifi-
cation of ERBB2, CCND1 and MYC, loss of PTEN and
CDH1, and missense mutations in TP53 and PIK3CA.
Some of these events have been associated with changes
in central metabolism in tumors and experimental sys-
tems [4,5,47-49]. Using these genetic alterations as cat-
egorical variables, we analyzed our data for signs of
metabolic signatures associated with the most common
genetic lesions. The co-existence of TP53 mutation and
reduced levels of a series of lipid glycerophosphocholines
was the most significant association detected. Altered
choline metabolism in the form of decreased glycero-
phosphocholine (GPC) was reported for several tumor
types, consistent with an association with p53 status
[50,51]. A specific connection between p53 and phospho-
lipid metabolism was demonstrated previously with indi-
cation of feedback regulation between phospholipid
turnover and p53 activity [52-55]. In our data, 8 differ-
ent long-chain fatty acid glycerophosphocholines were
strongly reduced in p53 mutant tumors suggesting an
underlying regulatory relationship for this consistent
association. An important caveat for this finding is the
fact that p53 mutation status is associated with the
basal intrinsic subtype in breast cancer. In our data
set, all five of the basal cancers harbored p53 muta-
tions and only one of the nonbasal cancers (HER2) had
a mutation. Therefore, the strong association we observed
between TP53 status and the levels of these phospholipids
may be confounded by intrinsic subtype something that
cannot be distinguished in the current study. Another in-
teresting metabolite-genetic association is the higher level
of fucose in ERBB2+ tumors. Fucose is a simple sugar that
is used to modify proteins and shown to be necessary for
key functions of neoplastic progression of breast cancer
cells [56]. The higher level of fucose may suggest that such
glycoprotein modifications play a particular important role
in ERBB2+ tumors.
Our findings with respect to BRCA1 further highlight
the potential of these joint analyses. Germ line BRCA1
mutations typically lead to triple-negative cancers, but
broad variation in mRNA expression is also observed
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levels of BRCA1 mRNA were positively correlated with
a group of metabolites indicative of elevated fatty acid
β-oxidation and increased anti-stress response and in-
versely correlated with medium- and long-chain fatty
acids and membrane components. BRCA1 protein via
its BRCT domain was shown to bind to ACC1/ACACA
preventing its dephosphorylation, keeping it in a phos-
phorylated and inactive form, thus inhibiting fatty acid
synthesis and promoting fatty acid β-oxidation [31].
We found a number of metabolites that fit this mechan-
ism. BRCA1 has also been implicated in redox homeosta-
sis [33], potentially through an interaction with NRF2 that
prevents its degradation and promotes its nuclear accu-
mulation [35] and we found multiple metabolites that also
fit this activity. These BRCA1 expression-metabolite asso-
ciations are entirely consistent with in vitro mechanistic
studies implicating BRCA1 in these processes and as such,
constitute direct support for the physiologic relevance of
these pathway connections in breast cancer.
Rate of proliferation is a key phenotypic property of
breast cancers that can be used as an independent prog-
nostic factor [57]. Gene expression indicative of prolifer-
ation constitutes a major component of the OncotypeDx
multi-gene recurrence score [58]. We measured prolifer-
ation in our specimens by scoring Ki-67 staining as a
continuous variable and correlated this metric with me-
tabolite levels. As anticipated, a number of strong corre-
lations with proliferative rate were found including high
levels of lactate and low levels of glucose consistent with
glucose-consumption patterns in rapidly growing cells.
Overall, many of the same metabolites correlated with
both receptor status and proliferation. While prolifera-
tion did correlate with ER status in our study (and
others), there were ER + cancers with high proliferation
rates and ER- cancers with relatively low proliferation
rates in our sample set. We compared the relative con-
tribution of these two factors (proliferation and receptor
status) to metabolite levels through statistical analysis
and found that a number of analytes were strongly asso-
ciated with one parameter but not the other suggesting
that there is some degree of independence. However,
these results further highlight the potential confounding
classification issue in breast cancer as receptor status,
intrinsic subtype, and genetic and phenotypic properties
are all correlated. The admixture of cancers we analyzed
in the current study reinforces these relationships indi-
cating that this data set is highly representative of the
landscape of the disease. The inclusion of metabolite
profiles as an additional dimension in the TCGA data-
base provides a new level of resolution to this important
public resource. Indexing our metabolite data to the
rigorously curated, comprehensive, and standardized
TCGA platform offers the opportunity for additionalhypothesis testing and discovery based upon metabolic
signatures and could produce novel insights for detec-
tion, prognostic, predictive, or therapeutic benefit.
Conclusions
We have identified categorical differences in the metabolic
profile of ER- vs. ER + breast tumors that may directly im-
pact tumor behavior and clinical phenotypes. We found
notable differences in energy needs, redox potential, pro-
tein uptake and catabolism which in the ER- samples
correlated with increases in glutathione biosynthesis,
NAD + production, and proliferative signaling. The data
are consistent with high Warburg metabolism in the ER-
tumors, as several biochemical intermediates of the glyco-
lytic pathway including lactate were found to be increased
in these cancers. Joint analysis with genetic alterations fur-
ther identified several gene-metabolite correlations valid-
ating the physiologic relevance of reported in vitro
associations and providing indications of novel regula-
tory relationships between tumor genetics and metab-
olism. The addition of metabolomic data to the public
domain TCGA dataset provides an important new tool
for the discovery and hypothesis testing of the genetic
regulatory of tumor metabolism.
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